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Background
Phase III clinical trials in areas including acute stroke
and traumatic brain injury commonly use ordinal func-
tional outcome scales as their primary outcome mea-
sure. Conventionally these scales are analysed by
dichotomising the ordinal scale into a binary scale:-
‘dead or dependent’ versus ‘independent’. This can
potentially discard much relevant information, reducing
both the clinical relevance of the results and the statisti-
cal efficiency of the analysis.
Methods
Methodological work in stroke (by the OAST Group)
and in traumatic brain injury (by the IMPACT Investi-
gators) has demonstrated that using more appropriate
approaches to the analysis of ordinal outcome scales,
such as proportional odds regression or the ‘sliding
dichotomy’, can potentially lead to substantial efficiency
gains relative to the conventional dichotomous analysis.
However, to date relatively few trials have prospectively
adopted ordinal techniques for their primary analysis.
We report here how in SCAST [1], a major Phase III
trial of blood pressure reduction in acute stroke, ordinal
methods were adopted for the primary analysis of the
modified Rankin Scale (mRS), an ordinal functional out-
come scale.
Results
Since ordinal methodology was evolving in parallel with
the conduct of the trial, the Statistical Analysis Plan was
not finalised until close to database lock. It was decided
to use proportional odds regression for the primary
analysis of the mRS with the sliding dichotomy as a sen-
sitivity analysis. Relative to a conventional dichotomous
analysis both of these approaches did indeed lead to
substantial efficiency gains, equivalent to more than
doubling the sample size.
Conclusions
SCAST shows that the potential efficiency gains demon-
strated in basic methodological research can be realised
in practice. This has major implications for the design
and analysis of future trials based on ordinal outcome
scales.
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